Prostate Specific Antigen (PSA) test is a blood test useful in screening and diagnosis of prostate cancer or other prostate related disorders. PSA is a chemical made by the prostate gland and is produced by both cancerous and non-cancerous prostate tissues. This test estimates the amount of ...
transrectal ultrasound (TRUS), prostate specific antigen (PSA) and age-related PSA values, gland-volume-adjusted PSA levels, and longitudinal PSA changes were analyzed to identify their cost-effectiveness as prognostic indicators in screening, biopsy, and follow-up of patients with prostate canc...
BACKGROUNDThe Prostate Cancer Prevention Trial (PCPT) demonstrated that finasteride reduces the prevalence of prostate cancer by 24.8% (risk reduction) but questions remain regarding the cost-effectiveness of widespread utilization. The purpose of the current analysis was to evaluate the cost-effectiveness...
Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2015;107:366.Heijnsdijk EAM, deCarvalho TM, Auvinen A et al. Cost-effectiveness of prostate ...
Black males are more likely to get prostate cancer and maybe diagnosed at a younger age. How do I order PSACheck? You can order your PSACheck at-home sample collection test kit here. The test kit will be delivered to your home in discreet packaging. The cost of the PSACheck is £...
Aff ordable cancer care 2 Evidence-informed frameworks for cost-eff ective cancer care and prevention in low , middle, and high-income countries prevention of tobacco-related cancers; secondary prevention of cancers of the cervix, mouth,breast at tertiary care institutions for leadership in research...
Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Non-Invasive Colorectal Cancer Screening BACKGROUND: Biomarker assays could increase the accuracy of non-invasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estima... I Lansdorp-Vogel...
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437-450. doi:10.1111/j.1464-410X.2012.11597.x PubMedGoogle ScholarCrossref 31. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R...
PSA testing has lowered the number of deaths from prostate cancer. However, it's hard to say, on an individual level, whether the test's benefits outweigh the cost and risk of potential side effects. Some advantages to having a PSA test include: ...
Prostate-specific antigen (PSA) and prostate health index (PHI) have been used as biomarkers for prostate cancer detection. In this study, we aimed to evaluate the cost-effectiveness of PHI for prostate cancer detection in Chinese men. We developed a Mar